Introducing Tempus One in the EHR with Integrated Guidelines

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of Tempus One—its generative AI clinical assistant—with direct integration into electronic health record (EHR) systems. By integrating AI at every point of the clinical care process, the expanded capabilities of Tempus One offer physicians in oncology and beyond more support in treatment decisions. Tempus One is uniquely positioned to offer these new features given the company's depth and scale of EHR integrations with providers across the U.S.
Tempus has developed an integrated architecture that captures real-time clinical, molecular and imaging data from millions of patients and makes that data easily digestible and useful for clinicians and care teams. Through Tempus One, physicians can gain AI-enabled insights that transform how they interact with patient data, streamlining complex treatment decisions and reducing time spent on administrative tasks.
New capabilities in the latest iteration of Tempus One:
Integration of ASCO Guidelines: Tempus One is integrating ASCO's clinical practice guidelines into the platform to equip physicians with the latest guidelines and information to guide personalized patient care. Oncologists are now able to easily access ASCO's guidelines, which provide evidence-based, treatment and care recommendations.
Clinical Workflow Assistance: Tempus One has a suite of new features, designed to help physicians at every step with tailored insights and reduce the burden of administrative tasks.
Pre-Appointment Preparation: Tempus One summarizes patient history, treatment journey, and recent biomarker status, ensuring physicians are well-prepared for appointments.
Real-Time Support During Appointments: Tempus One can transcribe conversations, take intelligent notes, and highlight key information, allowing physicians to focus on patient care.
Post-Appointment Assistance: Tempus One supports documentation tasks, treatment planning based on updated guidelines and research, prepares prior authorizations, and facilitates clinical trial matching.
Agent Builder: Over the past several months, Tempus has used its Agent Builder GenAI tool internally to develop and deploy more than 1,000 AI agents. Now, Tempus is extending access to this toolset to a select group of partner providers, collaborating with them to create and test custom GenAI solutions tailored to their unique needs and preferences. The agents are designed to create efficiencies and streamline workflows, such as generating custom patient overviews to accelerate pre-charting or generating notes from conversations with patients to be added into their EHR records. These custom agents can be developed in collaboration with dedicated Tempus team members. By referencing institutions' standard operating procedures and data repositories, these agents can be seamlessly integrated into existing workflows through One.
'As healthcare faces rising costs and growing complexity, no group bears the burden more heavily than physicians and care teams,' said Ryan Fukushima, Chief Operating Officer at Tempus. 'This evolution of Tempus One represents a meaningful shift from a world where clinicians spend countless hours searching for answers and documenting care, to one where AI rapidly connects the dots across fragmented systems to deliver actionable insights in real time.'
To learn more about Tempus One, view a video here and visit the website here.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of Tempus One and its capabilities for customers. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

35 minutes ago

• Business Wire

CEA Opens Shanghai–Auckland–Buenos Aires "New International Land-Sea Trade Corridor" to First Bridge China and South America

SHANGHAI--(BUSINESS WIRE)--On June 18, 2025, China Eastern Airlines (CEA) and Auckland Airport signed a cooperation agreement in Shanghai. According to the plan, CEA will launch commercial flights in December 2025 from Shanghai Pudong International Airport to Ministro Pistarini International Airport via Auckland Airport. The signing ceremony was attended by government officials, corporate representatives, and heads from relevant departments. New Zealand's Prime Minister Christopher Luxon highlighted that the new route will enhance global connectivity by linking Auckland with the dynamic economies of Asia and South America. He also announced that New Zealand will implement a visa-free transit policy for Chinese travelers passing through Auckland. Since the opening of the route to Auckland in 2014, CEA has shown strong growth. Chairman Wang Zhiqing stated that the airline will leverage its Shanghai hub to accelerate the construction of its global route network. The new route will serve as a vital bridge among New Zealand, China, the Asia-Pacific region, and South America, supporting the Belt and Road Initiative. Auckland Airport expressed satisfaction with the imminent realization of the jointly envisioned " New International Land-Sea Trade Corridor". CEA, Auckland Airport's key partner and now the leading carrier on the China–New Zealand route, has maintained steady operations and consistently expanded capacity. The new service, to be operated twice weekly by Boeing 777, will be the only direct air link between Argentina and China, filling the gap in direct air services between the two nations. The "New International Land-Sea Trade Corridor" shortens travel time by 4–5 hours versus European or North American routes and offers direct flights, while also reducing jet lag—passengers only face a 4-hour time difference when transiting through Auckland, as opposed to 12 hours via traditional Western routes. CEA plans to apply for fifth freedom for this route, enabling passenger and cargo transport in Auckland, boosting economic, trade, and people-to-people exchanges among New Zealand, China, and Argentina. Currently, CEA operates flights from Auckland to both Shanghai Pudong and Hangzhou Xiaoshan. Following the new route launch, CEA will boost New Zealand–China capacity deployment, increasing Auckland–Shanghai flights from 7 to 9 weekly. Note: The new route remains subject to final regulatory approval.

Business Upturn

2 hours ago

• Business Upturn

IT Stocks Fall: Infosys, LTI Mindtree, TCS and other stocks decline up to 3% following Accenture results

By Aditya Bhagchandani Published on June 23, 2025, 09:40 IST IT stocks witnessed a sharp decline of up to 3% on June 23, after global technology major Accenture narrowed its full-year revenue growth guidance, sparking concerns over demand headwinds in the sector. Investors reacted negatively to the earnings update released last Friday, which failed to offer strong incremental cues for Indian peers. Infosys emerged as the top loser on the Nifty IT index, slipping 2% to Rs 1,516.85. Shares of HCL Technologies, TCS, and Oracle Financial dropped between 1% and 2%, while LTI Mindtree fell 1.34% to Rs 5,160.65. Persistent Systems and Coforge declined 0.82% and 0.80%, respectively. The broader Nifty IT index was down 0.80% at 36,872.60. Accenture reported 7% year-on-year revenue growth in the latest quarter and narrowed its FY guidance to 6–7%, from the earlier range of 5–7%. While the company reported strength in its financial services vertical—a key segment for Indian IT firms—its lower guidance and weak outsourcing bookings raised investor caution. Brokerage firm HSBC noted that the results lacked any strong positive read-through for Indian IT stocks, even as Gen AI bookings grew. CLSA, however, maintained a positive outlook on the Indian IT space, with Infosys, Tech Mahindra, and Persistent Systems as its top picks, while maintaining caution on LTIMindtree. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

Yahoo

3 hours ago

• Yahoo

AeroVironment (AVAV) Reports Earnings Tomorrow: What To Expect

Aerospace and defense company AeroVironment (NASDAQ:AVAV) will be announcing earnings results this Tuesday afternoon. Here's what investors should know. AeroVironment missed analysts' revenue expectations by 10.9% last quarter, reporting revenues of $167.6 million, down 10.2% year on year. It was a disappointing quarter for the company, with full-year revenue guidance missing analysts' expectations significantly and full-year EBITDA guidance missing analysts' expectations significantly. Is AeroVironment a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting AeroVironment's revenue to grow 23.7% year on year to $243.7 million, improving from the 5.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.41 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. AeroVironment has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 5.6% on average. Looking at AeroVironment's peers in the aerospace and defense segment, some have already reported their Q1 results, giving us a hint as to what we can expect. HEICO delivered year-on-year revenue growth of 14.9%, beating analysts' expectations by 3.5%, and Redwire reported a revenue decline of 30.1%, falling short of estimates by 16.5%. HEICO traded up 7.4% following the results while Redwire's stock price was unchanged. Read our full analysis of HEICO's results here and Redwire's results here. Investors in the aerospace and defense segment have had steady hands going into earnings, with share prices flat over the last month. AeroVironment is up 7.2% during the same time and is heading into earnings with an average analyst price target of $195.38 (compared to the current share price of $190.94). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.